TTrialPathMatch Me to Trials
← Back to trials
RecruitingCancer, Hepatocellular

To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this prospective observational study is to test the impact of addition of the GAAD score to imaging in patients with chronic liver disease eligible for HCC surveillance. The main questions it aims to answer are: * Diagnostic accuracy of the GAAD score (cut-off 2.57 (3)) for detection of HCC (overall and by BCLC stage), expressed using sensitivity, specificity, negative predictive value and positive predictive value. * Change in GAAD score over time, and proportion of patients with a GAAD score above the cut-off over time in relation to potential confounding factors (e.g. age, bilirubin levels, presence of HCC). 1000 participants with chronic liver disease eligible for HCC surveillance will be enrolled. Data will be collected for 3 consecutive years after enrollment. As per clinical practice, patients will undergo standard bi-annual HCC surveillance comprising liver imaging with ultrasound (or CT or MRI based on previous investigations) and GAAD score assessment based on blood samples.

Sponsor: Erasmus Medical Center

You may qualify if…

  • ✓ All patients with cirrhosis
  • ✓ Non-cirrhotic chronic hepatitis B patients meeting any of the following criteria: positive family history for HCC, intermediate-high aMAP and/or (m)PAGE-B score (if non-Caucasian)
  • ✓ Non-cirrhotic chronic hepatitis C patients (with or without SVR) with a history of F3 fibrosis (based on histology or liver stiffness assessment)
  • ✓ Non-cirrhotic NASH patients with a history of F3 fibrosis (based on histology or liver stiffness assessment)

You may not qualify if…

  • ✕ Diagnosis with any other cancer other than non-melanoma skin cancer
  • ✕ History of HCC
  • ✕ Women who are pregnant or lactating
  • ✕ Patient with glomerular filtration rate \<45 ml /min/1.73 m2
  • ✕ Unwillingness or inability to undergo both CT and MRI imaging
  • ✕ Life expectancy \<2 years
  • ✕ Use of vitamin K antagonists

Source: ClinicalTrials.gov · NCT06601231 · last updated 2024-09-19

To Quantify the Impact of Addition of the GAAD Score to Imaging in Pat · TrialPath